Please login to the form below

Not currently logged in
Email:
Password:

LigoCyte

This page shows the latest LigoCyte news and features for those working in and with pharma, biotech and healthcare.

Takeda starts trial of norovirus vaccine

Takeda starts trial of norovirus vaccine

Takeda acquired rights to TAK-214 when it bought US biopharma company LigoCyte in 2012 in a $60m deal and says it remains the only norovirus vaccine candidate in clinical development.

Latest news

More from news
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest Intelligence

  • Pharma deals during October 2012 Pharma deals during October 2012

    The LigoCyte acquisition is part of the expansion of Takeda's recently formed Vaccine Business Division. ... 90+. ‡Theravance / Alfa Wasserman. Development, commercialisation &option. Velusetrag for gastroparesis (phase IIa)  . 64. LigoCyte /Takeda.

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Novasecta

We are a specialist strategy consulting firm for pharmaceutical and biotech companies. We help our clients to achieve significant performance...

Latest intelligence

Using human insights to push healthcare communications forward
This blog highlights the value of human perspectives, showing how insights can propel healthcare communications forward to ultimately improve lives...
RWE Blog 4: The place of real-world evidence in the market access strategy
The fourth and final blog in our latest series focuses on market access strategy. This follows our evaluation of the role of real-world data (RWD) and real-world evidence (RWE) in...
RWE Blog 3: Is real-world evidence the holy grail
We began our four-blog series by evaluating the role of real-world data (RWD) and real-world-evidence (RWE) in Real-world challenges and real-world data, and understanding the payer's perspective, in Payers use...

Infographics